Академический Документы
Профессиональный Документы
Культура Документы
1: Idiopathic Polyneuritis
2 : Acute Febrile Polyneuritis
3: Infective Polyneuritis
4: Post Infectious Polyneuritis
5 : Acute Inflammatory Demyelinating
Polyradiculoneuropathy
Saltatory conduction
Immunobiolog
y of GBS
Doorn 4/27/16
PA,et.al. Lancet Neurolo 2008;7:939-50
.
PATHOGENESIS
-Trauma
-Entrapment
-Tumor
-GBS
-Metabolic
-Nutritional
Dying Back
- Toxin
- Nutritional
AIDP
(DEMYELINATI
NG)
AIDP +
Secondary
Degeneration
AXONAL
PATTERN
MILLER
FISHERS
SYNDROME
AMAN
AMSAN
(Acute Motor
Sensory Axonal
Neuropathy)
PIN PERDOSSI,
SOLO, 6-8
NOVEMBER 2014
11
AMAN :
Pure motor Axonal Subtype
Onset to 1st Exam < (more rapidly) (<AIDP)
Onset to PEAK of clinical syndrome > rapid
13
ELECTROPHYSIOLOGY
STUDY
AIDP (DEMYELINATION)
16
-Terapi spesifik :
A. Kortikosteroid
-Prednison 15 mg/ hari 4 kali selama 1 minggu,
-Methyl prednisolon 500 mg intravena sehari sekali selama 5 hari
B. Plasmapharesis dosis 200 250 ml/kg BB dalam 4-6 x pemberian.
C.Imunoglobulin intravena : IVIG dosis 0,4 gr/ kgBB/ hari selama 5 hari
(pilihan yang terbaik).
First-line Therapies :
Advantages and Disadvantages
Therapy
Advantages
Disadvantages
IGIV
-Early results.
-Class I evidence
supports use
-Expensive, invasive
-Some contraindications, AEs
- Short-lived efficacy.
Corticosteroi
ds
-
-Inexpensive
-Easy to administration
-Early results.
-Class I evidence
supports use.
Methylprednisolo
n 500 mg/day ( 5
days)
Plasma
Exchanges
TPE
Early response.
Predictable.
Low risk of renal failure.
Procedure carries no
risk of unknown
infection.
Provides proof of
concept of antibody
mediated disease.
Proven efficacy in CNS
diseases (NMO, acute
demyelination).
Complications largely
preventable.
IvIG
1-2 weeks of delay.
Variable response.
Risk exists in IgA
deficiency.
Not necessarily safe for
new or emerging
infections.
Made of immune
modulation not direct.
CNS efficacy uncertain
(BBB penetration ).
Unpredictable
complication (e.g.
sterile meningitis ).
PLASMA EXCHANGE
4/27/16
24
Principle of procedures
(SPECTRA OPTIA)
SEPARATION BY CENTRIFUGATION
Centrifugation
Separation based on
specific gravity
Continuous flow
Process of Therapeutic
Apheresis
Drawn
2
6
Centrifu
ge
Collectio
n
Process
Monitor
Function of Therapy
1.1.Guillain-Barr
syndrome (GBS)
Sickle Cell
Disease
Thrombocytosis:
> 500,000 WBC*or
1.
Cartilage
deffect
Leukocytosis:
> 100,000/L
Neutropenia
2.2.1,000,000/L
Myasthenia
Gravis
Malaria
platelets*
2. Leukemia
Theurapetic Plasma
Exchange
Plasma
Platelet
Depletion
WBC
Depletion
Platelet
White Blood
Cell
RBC
2
7
Limfosit
Monosit
Granulosit
MNC Collection
Granulocyte
Collection
RBC Exchange
Neurologic
Disease
Category
Lambert-Eaton myasthenia
II
Multiple Sclerosis
III
Myasthenia Gravis
II
III
AABB/ASFA Guidelines
Category I: